Currently, phase II clinical trials are being conducted to test the efficacy of anti-PD-1 blocking antibodies in the context of MPN (NCT02421354, NCT03065400; source: https://clinicaltrials.gov). Here, PDCD1 is linked to myeloproliferative disorder.